The HPV vaccine market: Cervarix™™ competes with Gardasil®®

Author： Bornstein Jacob  

Publisher： Future Medicine

ISSN： 1475-0708

Source： Therapy, Vol.7, Iss.1, 2010-01, pp. : 71-75

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

FDA approves Gardasil 9 for more types of HPV

By  

CANCER, Vol. 121, Iss. 8, 2015-04 ,pp. : 1156-1157

John Wiley & Sons Inc

Access to resources Recommend Favorite

HPV vaccine acceptance in male adolescents

By  

PSYCHO-ONCOLOGY (ELECTRONIC), Vol. 24, Iss. 10, 2015-10 ,pp. : 1327-1329

John Wiley & Sons Inc

Access to resources Recommend Favorite

HPV vaccine uptake remains low

By  

CANCER, Vol. 119, Iss. 16, 2013-08 ,pp. : 2947-2948

John Wiley & Sons Inc

Access to resources Recommend Favorite

HPV-16 (and possibly HPV-18) is different: implications for screening before and after an HPV vaccine

By Hildesheim Allan  

Papillomavirus Report, Vol. 16, Iss. 6, 2005-11 ,pp. : 395-396

Maney Publishing

Access to resources Recommend Favorite

Behavioral Frequency Moderates the Effects of Message Framing on HPV Vaccine Acceptability

By Gerend Mary  

Annals of Behavioral Medicine, Vol. 35, Iss. 2, 2008-04 ,pp. : 221-229

Springer Publishing Company

Access to resources Recommend Favorite